Discovery of anticancer polymeric drugs that mimic the action of TRAIL

Información del proyecto

PolyDrug Discovery

Identificador del acuerdo de subvención: 703466

DOI

10.3030/703466

Proyecto finalizado el 1 Enero 2017

Fecha de la firma de la CE 10 Febrero 2016

Fecha de inicio 1 Marzo 2016

Fecha de finalización 28 Febrero 2018

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 173 857,20

Aportación de la UE

€ 173 857,20

Coordinado por

KAROLINSKA INSTITUTET
Sweden

Periodic Reporting for period 1 - PolyDrug Discovery (Discovery of anticancer polymeric drugs that mimic the action of TRAIL)

Período documentado: 2016-03-01 hasta 2018-02-28

Resumen del contexto y de los objetivos generales del proyecto

The objective of this project was to develop a polymeric drug (PolyDrug) that mimics the activity of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) for the treatment of breast cancer. Having such a polymeric and therefore synthetic replacement for this therapeutic would have tremendous benefits including greater drug stability and biodistribution. Therefore, this project outlined a two year plan to develop such a drug by following the standard drug discovery process.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

While this fellowship is being terminated early, I have achieved the goals set out over this 10 month period. This progress is critical as I plan to continue this project in my lab at Rutgers University. I was successful in preparing a variety of death receptor targeting peptides and managed to select a few peptides with low nM affinity towards this receptor. This was a main objective of this first year and these peptides will move on to further evaluation in my new position. During this first year, I also optimized the technique for preparing the polymers and showed that we are able to make all drug variations needed for the drug discovery process. In parallel, I also developed the drug screening cell culture assay that is need to run the drug discovery process. This culmination of this work puts me on target with the fellowship in order to continue at Rutgers University.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

This project is ongoing in my new position and the expected impact is still to be determined. Hopefully in one years time (as originally outlined), we will have a better update on the overall impact of this research.

combinatorial-low-volume-synthesis-of-well-def.jpg